EPFL

💉 👩‍⚕️ Scientists from our institution and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated on a GLP-1 receptor agonist candidate for diabetes and obesity treatment.

#AstraZeneca #DiabetesResearch #PharmaceuticalScience

Read more: https://go.epfl.ch/A1U-en

Cracking the code of amorphous drugs for diabetes treatment

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated on a GLP-1 receptor agonist candidate for diabetes and obesity treatment.

May 16, 2025 at 12:44pmWeb